

European Society for Medical Oncology

ESMO Breast Cancer 2022

May 3-5, 2022



You are entering a medical section of the Pfizer Landing Page. All materials here are presented for purposes of scientific exchange. They are NOT presented for any promotional purpose.

Wednesday, May 4, 2022

Poster Display Session

Exhibition Area

12:15–13:00 CEST

Palbociclib169P

Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis

Rugo HS



Palbociclib190P

Palbociclib treatment in pre/perimenopausal women with advanced/metastatic breast cancer (ABC/mBC): real-world patient characteristics, treatment patterns, and outcomes data from POLARIS

Karuturi M

